JP2017528431A5 - - Google Patents

Download PDF

Info

Publication number
JP2017528431A5
JP2017528431A5 JP2017502821A JP2017502821A JP2017528431A5 JP 2017528431 A5 JP2017528431 A5 JP 2017528431A5 JP 2017502821 A JP2017502821 A JP 2017502821A JP 2017502821 A JP2017502821 A JP 2017502821A JP 2017528431 A5 JP2017528431 A5 JP 2017528431A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
inhibitor
composition
active
metformin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017502821A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528431A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/040879 external-priority patent/WO2016011335A1/en
Publication of JP2017528431A publication Critical patent/JP2017528431A/ja
Publication of JP2017528431A5 publication Critical patent/JP2017528431A5/ja
Pending legal-status Critical Current

Links

JP2017502821A 2014-07-17 2015-07-17 器官再生のための内因性回腸ブレーキホルモン経路の活性化、並びに関連する組成物、治療方法、診断、及び制御システム Pending JP2017528431A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462025714P 2014-07-17 2014-07-17
US62/025,714 2014-07-17
PCT/US2015/040879 WO2016011335A1 (en) 2014-07-17 2015-07-17 Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems

Publications (2)

Publication Number Publication Date
JP2017528431A JP2017528431A (ja) 2017-09-28
JP2017528431A5 true JP2017528431A5 (enExample) 2018-08-16

Family

ID=55079079

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017502821A Pending JP2017528431A (ja) 2014-07-17 2015-07-17 器官再生のための内因性回腸ブレーキホルモン経路の活性化、並びに関連する組成物、治療方法、診断、及び制御システム

Country Status (9)

Country Link
US (1) US20170173060A1 (enExample)
EP (1) EP3169331A4 (enExample)
JP (1) JP2017528431A (enExample)
KR (1) KR20170026635A (enExample)
CN (1) CN106687119A (enExample)
AU (1) AU2015289511A1 (enExample)
CA (1) CA2955425A1 (enExample)
IL (1) IL250170A0 (enExample)
WO (1) WO2016011335A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8999721B2 (en) 2009-10-23 2015-04-07 Therabrake, Inc. Method and system to provide personalized pharmaceutical compositions and dosages
US20180099001A1 (en) 2011-04-29 2018-04-12 Volant Holdings Gmbh Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof
EP3294308A4 (en) 2015-05-14 2019-03-06 University of Puerto Rico PROCESS FOR RECOVERING THE BIOZOOSE OF NEWBORN
CA3009506A1 (en) 2015-12-23 2017-06-29 The Johns Hopkins University Long-acting glp-1r agonist as a therapy of neurological and neurodegenerative conditions
WO2017117142A1 (en) 2015-12-28 2017-07-06 New York University Device and method of restoring microbiota of newborns
US10398389B1 (en) 2016-04-11 2019-09-03 Pricewaterhousecoopers Llp System and method for physiological health simulation
WO2017203367A2 (en) * 2016-05-22 2017-11-30 Volant Holdings Gmbh Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof
AU2018219367A1 (en) 2017-02-10 2019-09-19 Innovate Biopharmaceuticals, Inc. Compositions and methods for treating disease associated with permeability of intestinal epithelium
WO2018204918A1 (en) * 2017-05-05 2018-11-08 Ardelyx, Inc. Treatment of hepatic disorders
JP7446816B2 (ja) * 2017-09-08 2024-03-11 自然免疫制御技術研究組合 アルツハイマー病指標表示装置及び方法
KR102282490B1 (ko) 2018-01-12 2021-07-28 주식회사 엠디헬스케어 패칼리박테리움 프라우스니찌 유래 나노소포 및 이의 용도
WO2019138379A1 (en) * 2018-01-12 2019-07-18 Metimedi Pharmaceuticals Co., Ltd. Methods of treating chronic inflammatory diseases
EP3758676A1 (en) * 2018-03-02 2021-01-06 Novaliq GmbH Pharmaceutical compositions comprising nebivolol
CN112074197A (zh) * 2018-03-07 2020-12-11 安纳生物科技有限公司 用于ii型糖尿病及用于提供随着时间的持续的能量释放的组合物
US10803981B2 (en) 2018-10-15 2020-10-13 James Glenn Norman Applied artificial intelligence technology for hormone therapy treatment
WO2020081369A1 (en) * 2018-10-15 2020-04-23 James Glenn Norman Applied artificial intelligence technology for hormone therapy treatment
KR102104507B1 (ko) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법
MX2022003925A (es) 2019-10-11 2022-04-20 Hoffmann La Roche Dispositivos y metodos de determinacion de la dosis del farmaco.
TWI882058B (zh) * 2020-01-08 2025-05-01 加拿大商瑞斯弗洛吉克斯公司 以bet溴結構域抑制劑及二肽基肽酶4抑制劑之組合治療及/或預防主要不良心血管事件(mace)的方法
CN111427913B (zh) * 2020-03-19 2023-07-25 上海太美星云数字科技有限公司 数据处理方法、设备、服务器、系统和计算机可读介质
WO2022243459A1 (en) * 2021-05-19 2022-11-24 Charité - Universitätsmedizin Berlin Computer assisted method for the evaluation of cardiac metabolism
CN113362925B (zh) * 2021-06-29 2022-04-08 山东第一医科大学附属省立医院(山东省立医院) 一种自动良肢位控制方法及设备
CN114705871A (zh) * 2022-04-12 2022-07-05 复旦大学附属中山医院 8异前列腺素F2α在重度哮喘诊断中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
CA2538023A1 (en) * 2003-09-24 2005-04-07 Combinatorx, Incorporated Therapeutic regimens for administering drug combinations
MX2008001282A (es) * 2005-07-28 2008-03-24 Reliant Pharmaceuticals Inc Tratamiento con bloqueadores del canal del calcio de dihidropiridina y acidos grasos omega-3 y un producto de combinacion de los mismos.
BRPI0716196A2 (pt) * 2006-08-31 2013-11-12 Eurand Inc Sistemas de distribuição de fármacos que compreendem soluções sólidas de fármacos fracamente básicos.
US8999721B2 (en) * 2009-10-23 2015-04-07 Therabrake, Inc. Method and system to provide personalized pharmaceutical compositions and dosages
US20130273154A1 (en) * 2011-03-02 2013-10-17 Joseph M. Fayad Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes
AU2012223528A1 (en) * 2011-03-02 2013-10-24 Joseph M. Fayad Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a Hepatitis C virus infection
EP2943213A4 (en) * 2013-01-08 2016-08-17 Jerome Schentag ACTIVATION OF THE ENDOGENOUS HORMONE PATHWAY OF ILLEAL BRAKE FOR THE REGENERATION OF AN ORGAN AND ASSOCIATED COMPOSITIONS, METHODS OF TREATMENT, DIAGNOSTICS, AND REGULATORY SYSTEMS

Similar Documents

Publication Publication Date Title
JP2017528431A5 (enExample)
ES2307463T3 (es) Forma de dosificación de combinación que contiene un agente reductor del colesterol, un inhibidor de la renina-angiotensina, y aspirina.
KR102103426B1 (ko) 당뇨병 신규 발병 저감용 조성물
JP2015503593A5 (enExample)
EP3581173B1 (en) Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation
HRP20210686T1 (hr) Pripravci i postupci za liječenje moždanog udara kod subjekta na istodobnoj terapiji statinom
JP5204846B2 (ja) エタノールの影響に対して耐性を有する非オピオイド薬のpH依存性制御放出医薬組成物
JP2015522029A5 (enExample)
JP5453434B2 (ja) エタノールの影響に対する耐性を有するオピオイドではないpH依存の制御放出の医薬組成物
JP2019048843A5 (enExample)
JP2017528516A5 (enExample)
JP2015503590A5 (enExample)
US20110311631A1 (en) Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients
ES2525648T3 (es) Formulaciones galénicas que comprenden Aliskiren
RU2018120726A (ru) Комбинации с гемкабеном для лечения заболеваний сердечно-сосудистой системы
FI3936130T3 (fi) Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon
ES2623176T3 (es) Composición farmacéutica de memantina
CN102065847A (zh) 含有血管紧张素-ⅱ受体阻断剂的药物制剂
KR20110128869A (ko) 중성 비닐 중합체 및 부형제를 포함하는 코팅을 이용하는, 에탄올의 영향에 대한 내성을 갖는 제어 방출 제약 조성물
Bader et al. Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro
KR20090114325A (ko) 약제학적 제제
RU2014127884A (ru) Способы лечения сердечно-сосудистого нарушения
CN101980701A (zh) 用于预防心血管疾病的胶囊
CN103501768A (zh) 具有抗乙醇影响抗性的抗胃酸的药物或营养组合物
ES2299072T3 (es) Procedimiento para la preparacion de formas medicamentosas con perfil de liberacion de principio activo estable.